HC Wainwright Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics (NASDAQ:DFTX) had its price target upped by investment analysts at HC Wainwright from $55.00 to $70.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 295.70% from the company’s previous close.

DFTX has been the topic of several other reports. Canaccord Genuity Group upped their price objective on shares of Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, November 7th. Wolfe Research started coverage on shares of Definium Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Thursday, January 22nd. Jefferies Financial Group assumed coverage on shares of Definium Therapeutics in a research note on Thursday, January 29th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Robert W. Baird set a $37.00 target price on shares of Definium Therapeutics in a report on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $35.70.

Definium Therapeutics Stock Performance

Shares of DFTX opened at $17.69 on Monday. Definium Therapeutics has a 1 year low of $4.70 and a 1 year high of $18.70. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29. The stock’s fifty day moving average price is $15.81 and its two-hundred day moving average price is $12.95. The firm has a market cap of $1.74 billion, a PE ratio of -8.31 and a beta of 2.56.

Insiders Place Their Bets

In related news, CEO Robert Barrow sold 25,791 shares of the stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the sale, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the sale, the insider directly owned 282,576 shares of the company’s stock, valued at $3,715,874.40. This represents a 3.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 42,667 shares of company stock worth $561,071 in the last three months. 2.26% of the stock is currently owned by corporate insiders.

Institutional Trading of Definium Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada boosted its position in shares of Definium Therapeutics by 10.4% during the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after acquiring an additional 6,148 shares during the last quarter. CWM LLC raised its stake in Definium Therapeutics by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Definium Therapeutics by 9.4% during the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock valued at $106,000 after purchasing an additional 1,400 shares during the last quarter. Geode Capital Management LLC grew its stake in Definium Therapeutics by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after buying an additional 66,663 shares in the last quarter. Finally, Creative Planning grew its stake in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after buying an additional 1,655 shares in the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.